Company

Editas Medicine, Inc.

Headquarters: Cambridge, MA, United States

Founded: November 2013

Employees: 264

CEO: Mr. James C. Mullen

NASDAQ: EDIT -1.45%

Market Cap

$377.5 Million

USD as of July 1, 2024

Market Cap History

Editas Medicine, Inc. market capitalization over time

Evolution of Editas Medicine, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Editas Medicine, Inc.

Detailed Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Editas Medicine, Inc. has the following listings and related stock indices.


Stock: NASDAQ: EDIT wb_incandescent

Stock: FSX: 8EM wb_incandescent

Key People

Founder(s): Jennifer Doudna, Feng Zhang, George Church (geneticist), David R. Liu, J. Keith Joung

James Mullen (President and CEO)

Financials


Total assets: US$508,885,000 (2019)

Total equity: US$262,437,000 (2019)

Details

Headquarters:

11 Hurley Street

Cambridge, MA 02141

United States

Phone: 617 401 9000